Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRI	BER	PATIENT:		
Name:		Name:		
Ward:		NHI:		
Mening	ococcal B multicomponent vaccine			
Re-asses	ON – Primary immunisation for children up to 12 months of age sment required after 3 doses sites (tick boxes where appropriate)			
or	Three doses for children up to 12 months of age (inclusive) for Up to three doses (dependent on age at first dose) for a catch (inclusive) for primary immunisation, from 1 March 2023 to 31	n-up programme for children from 13 months to 59 months of age		
	ON – Person is one year of age or over sites (tick boxes where appropriate)			
or or or	Up to two doses and a booster every five years for patients present asplenia, HIV, complement deficiency (acquired or inherited), Up to two doses for close contacts of meningococcal cases of Up to two doses for person who has previously had meningococcal cases of Up to two doses for bone marrow transplant patients Up to two doses for person pre- and post-immunosuppression	occal disease of any group		
Re-asses	DN – Person is aged between 13 and 25 years (inclusive) asment required after 2 doses sites (tick boxes where appropriate)			
and		·		
	Immunosuppression due to corticosteroid or other immunosuppression 28 days.	sive therapy must be for a period of		

I confirm that the above details are correct:

0:	D - 1 - 1	
Zigneg.	i jate:	
Oigilica.	 Duic.	